Loading asset research
Protara Therapeutics Inc. Common Stock
TARANasdaq · USD · StocksQuote as of · Exchange session not verified$3.84
+1.32%
Today
TARA
Loading 1D prices…
Market cap
$225.7M
Volume
532K
52w high
$7.8252w low
$3.02Company profile
Protara Therapeutics Inc. Common Stock
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
46
Fiscal year end
1231
CIK
1359931
Session & valuation
Open$3.83
Previous close$3.79
Day high$3.95
Day low$3.81
30-day avg. volume359.4K
Outstanding shares59.1M
Diluted EPS-$1.34
Latest annual period
P/E (trailing)-2.87
P/E (forward)-2.26
Price / book1.40
Beta1.49
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SRZNSurrozen Inc. Common Stock | $223.3M | $3.5M | -6960.77% | -$32.37 | -2.31% | Buy |
| IVVDInvivyd Inc. Common Stock | $231.5M | $53.4M | -98.25% | -$0.30 | +1.10% | Buy |
| CRDLCardiol Therapeutics Inc. Class A Common Shares | $233.1M | — | — | -$0.39 | +0.76% | Buy |
| CGENCompugen Ltd. Ordinary Shares | $234M | $72.8M | +48.57% | $0.38 | +0.61% | Buy |
| ALECAlector Inc. Common Stock | $238.9M | $21M | -679.50% | -$1.39 | +0.00% | Hold |